S15 Ep31: Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium
In this podcast, experts Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD, discuss frontline, second-line, and antibody-drug conjugate therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.
32m Jan 20
32m
S15 Ep30: Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms
In this podcast, experts Tiffany A. Traina, MD, FASCO, Kevin Kalinsky, MD, MS, FASCO, Mark E. Robson, MD, FASCO, and Rebecca Shatsky, MD discuss data for CDK4-6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors in the management of early-stage hormone receptor-positive, HER-2-negative breast cancer.
30m Jan 20
30m
S15 Ep29: Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy
In this podcast, experts Scott T. Tagawa, MD, MS, FASCO, FACP; Himisha Beltran, MD; and Neeta Pandit-Taskar, MD, MBA, discuss the latest evidence on PSMA PET and RLT, including combination strategies, selection, sequencing, toxicity monitoring, and operations, with careful attention to access and equity.
27m Jan 20
27m
S15 Ep28: Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP
Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with IMiDs.
19m Jan 16
19m
S15 Ep27: Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life
In this podcast, experts Sara A. Hurvitz, MD, FACP, Michelle Melisko, MD, and Paolo Tarantino, MD, PhD, discuss approaches to maintenance and subsequent lines of therapy for patients with HER2+ advanced breast cancer, including those with CNS metastases.
22m Jan 16
22m
S15 Ep26: FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD
Dr Falchi discusses why the FDA approval of epcoritamab plus lenalidomide/rituximab is clinically meaningful for relapsed/refractory follicular lymphoma.
18m Jan 15
18m
S15 Ep25: FDA Approval Insights: BVd for Relapsed/Refractory Multiple Myeloma: With Surbhi Sidana, MD
In today’s episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin...
9m Jan 09
9m
S15 Ep24: PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD
In today’s episode, the discussion features Jonathan R. Strosberg, MD, a professor and leader in the Neuroendocrine Tumor Division and the Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Florida, who reviewed the clinical implications of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide (ITM-11) for patients with metastatic gastroent...
8m Jan 07
8m
S15 Ep23: Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD; and Valentina Bonev, MD, DABS, FACS, FSSO
In this episode of Precision and Progress: Radiotherapy in Oncology, Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, co-hosted a discussion with Valentina Bonev, MD, DABS, FACS, FSSO, about the interplay between surgery and radiation in breast cancer care.
26m Jan 05
26m
S15 Ep22: CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD
Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.
22m Dec 31, 2025
22m
S15 Ep21: FDA Approval of Enfortumab Vedotin/Pembrolizumab Redefines Perioperative Care for Cisplatin-Ineligible MIBC: With Christof Vulsteke, MD, PhD
Dr Vulsteke discusses the FDA approval of enfortumab vedotin-ejfv plus pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer.
8m Dec 31, 2025
8m
S15 Ep20: Osimertinib Carves a Continuing Role in Perioperative NSCLC Management: With Julia Rotow, MD; and Gavitt Woodard, MD
Drs Rotow and Woodard talk through recent updates to the perioperative non–small cell lung cancer treatment paradigm.
22m Dec 29, 2025
22m
S15 Ep19: MRI Techniques Evolve for Glioma Diagnosis, Response Assessment, and Surveillance: With Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD
In today’s episode, we passed the mic to Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD, who led an OncLive Ask the Expert discussion on evolving imaging strategies in glioma.
25m Dec 25, 2025
25m
S15 Ep18: ctDNA Testing Opens Avenues for the Future of Breast Oncology: With Jason Mouabbi, MD
Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.
21m Dec 22, 2025
21m
S15 Ep17: Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD
Dr Phull reviews findings from a translational study that longitudinally profiled the fecal microbiome of patients with newly diagnosed myeloma.
7m Dec 18, 2025
7m
S15 Ep16: Ongoing Sigvotatug Vedotin Exploration Highlights Potential for Biomarker Advancement in NSCLC: With Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH
Drs Kim and Malhotra discuss factors that make IB6 unique vs other NSCLC biomarkers and the study of sigvotatug vedotin in previously treated NSCLC.
13m Dec 17, 2025
13m
S15 Ep15: ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
Drs Armstrong and Tawagi highlight chronic lymphocytic leukemia updates from the 2025 ASH Annual Meeting.
11m Dec 17, 2025
11m
S15 Ep14: Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD
Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.
33m Dec 11, 2025
33m
S15 Ep13: Hepatic Artery Infusion Refines Liver-Directed Care for GI Cancers: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
Drs Tiesi, Scholer, Golas, and Pletcher discuss the use of hepatic artery infusion in colon cancer and liver cancer management.
24m Dec 09, 2025
24m
S15 Ep12: VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.
9m Dec 05, 2025
9m
S15 Ep11: PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
Drs Tiesi, Scholer, Golas, and Pletcher discussed the use of PIPAC, a minimally invasive regional cancer therapy, in patients with peritoneal cancers.
33m Dec 03, 2025
33m
S15 Ep10: ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD
Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.
11m Dec 03, 2025
11m
S15 Ep9: Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS
Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.
4m Dec 02, 2025
4m
S15 Ep8: Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD
Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.
14m Dec 01, 2025
14m
S15 Ep7: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD
Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.
6m Nov 28, 2025
6m
S15 Ep6: Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS
Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.
6m Nov 27, 2025
6m
S15 Ep5: Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD
In today’s episode, we had the pleasure of speaking with Daniel Spratt, MD, chair and professor in the Department of Radiation Oncology at Case Western Reserve University School of Medicine and a member of the Case Comprehensive Cancer Center in Cleveland, Ohio. Dr Spratt discussed key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer, including how adva...
20m Nov 25, 2025
20m
S15 Ep4: Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD
In today’s episode,filmed live at the 43rd Annual CFS Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with breast cancer experts Kamel Abou Hussein, MD, and Victoria Rizk, MD, about the rapidly evolving therapeutic landscape in breast cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Ca...
17m Nov 24, 2025
17m
S15 Ep3: Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD
In today’s episode, we had the pleasure of speaking with Marc S. Raab, MD, about the post-induction outcomes and updated minimal residual disease (MRD) analyses from the phase 2 MajesTEC-5 study (NCT05695508), which is evaluating teclistamab-cqyv (Tecvayli)–based induction regimens in patients with newly diagnosed multiple myeloma. Dr Raab is a professor of medicine at Heidelberg University in ...
8m Nov 24, 2025
8m
S15 Ep2: FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
21m Nov 21, 2025
21m
S15 Ep1: Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD
In today’s episode, we had the pleasure of speaking with Justin Taylor, MD, an associate professor in the Division of Hematology at the University of Miami Miller School of Medicine, about the growing role of artificial intelligence in cancer information–seeking and what this means for clinicians caring for patients with hematologic malignancies. Dr Taylor’s recent work explores how patients ar...
15m Nov 19, 2025
15m
S14 Ep50: Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS
Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.
9m Nov 18, 2025
9m
S14 Ep49: Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
In today’s episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted an in-depth discussion with Jonathan W. Lee, MD, MSc, on the evolving therapeutic landscape for EGFR-mutant and HER2-positive non–small cell lung cancer (NSCLC). Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center...
28m Nov 14, 2025
28m
S14 Ep48: PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO
Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.
27m Nov 13, 2025
27m
S14 Ep47: Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis,
In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.
19m Nov 13, 2025
19m
S14 Ep46: Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS
Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.
5m Nov 11, 2025
5m
S14 Ep45: Urothelial ESMO 2025 Updates
OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.
13m Nov 11, 2025
13m
S14 Ep44: Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO
Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.
10m Nov 07, 2025
10m
S14 Ep43: ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD
Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.
11m Nov 06, 2025
11m
S14 Ep42: Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC
Dr Mian discussed why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic
5m Nov 06, 2025
5m
S14 Ep41: Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.
19m Nov 05, 2025
19m
S14 Ep40: Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS
Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medic...
5m Nov 04, 2025
5m
S14 Ep39: Oncology Experts Dive Into Top Data From ESMO 2025
At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
18m Nov 04, 2025
18m
S14 Ep38: Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS
Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.
12m Oct 31, 2025
12m
S14 Ep37: Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD
Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.
29m Oct 30, 2025
29m
S14 Ep36: Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD
Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.
27m Oct 29, 2025
27m
S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.
15m Oct 27, 2025
15m
S14 Ep34: FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS
Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.
12m Oct 23, 2025
12m
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.
33m Oct 23, 2025
33m
S14 Ep32: Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD
Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.
13m Oct 22, 2025
13m